Clal Bio Surges Most in Two Weeks as Unit Gets FDA Approval
Clal Biotechnology Industries Ltd. (CBI) advanced the most in two weeks after a unit got the U.S. Food and Drug Administration orphan drug status for its DiaPep277 treatment for juvenile diabetes.
The shares of the investment company advanced 4.9 percent, the most since May 8, to 13.06 shekels at 11:13 a.m. in Tel Aviv.
To contact the reporter on this story: Shoshanna Solomon in Tel Aviv at email@example.com
To contact the editor responsible for this story: Claudia Maedler at firstname.lastname@example.org